These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study. Lu Y; Sun RJ; Zhang JP; Xu F; Du ZC; Tong GL; Wang Y; Lu DP Leuk Lymphoma; 2022 Dec; 63(13):3092-3099. PubMed ID: 36067510 [TBL] [Abstract][Full Text] [Related]
8. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185 [TBL] [Abstract][Full Text] [Related]
9. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies. Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258 [TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy Combined with Venetoclax Followed by Allo-Hematopoietic Stem Cell Transplantation for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm]. Cheng P; Wang LL; Wang QX; Guan J; Zhou Y; Hu B; Feng Y; Zou L; Cheng H Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1531-1536. PubMed ID: 37846712 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. Dholaria BR; Ayala E; Sokol L; Nishihori T; Chavez JC; Hussaini M; Kumar A; Kharfan-Dabaja MA Leuk Res; 2018 Apr; 67():1-5. PubMed ID: 29407180 [TBL] [Abstract][Full Text] [Related]
12. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. Guru Murthy GS; Kim S; Hu ZH; Estrada-Merly N; Abid MB; Aljurf M; Bacher U; Badawy SM; Beitinjaneh A; Bredeson C; Cahn JY; Cerny J; Diaz Perez MA; Farhadfar N; Gale RP; Ganguly S; Gergis U; Hildebrandt GC; Grunwald MR; Hashmi S; Hossain NM; Kalaycio M; Kamble RT; Kharfan-Dabaja MA; Hamilton BK; Lazarus HM; Liesveld J; Litzow M; Marks DI; Murthy HS; Nathan S; Nazha A; Nishihori T; Patel SS; Pawarode A; Rizzieri D; Savani B; Seo S; Solh M; Ustun C; van der Poel M; Verdonck LF; Vij R; Wirk B; Oran B; Nakamura R; Scott B; Saber W JAMA Oncol; 2022 Mar; 8(3):404-411. PubMed ID: 35024768 [TBL] [Abstract][Full Text] [Related]
13. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma. Furqan F; Ahn KW; Chen Y; Kaur M; Abutalib SA; Ahmed N; Ahmed S; Kharfan-Dabaja MA; Friedberg J; Gregory T; Hill L; Sterling C; Barta SK; Shadman M; Perales MA; Zain J; Herrera AF; Sauter C; Hamadani M Br J Haematol; 2023 Jan; 200(1):54-63. PubMed ID: 36120837 [TBL] [Abstract][Full Text] [Related]
14. Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Ortí G; Gras L; Zinger N; Finazzi MC; Sockel K; Robin M; Forcade E; Avenoso D; Kröger N; Finke J; Radujkovic A; Hunault-Berger M; Schroyens W; Zuckerman T; Bourhis JH; Chalandon Y; Bloor A; Schots R; de Wreede LC; Drozd-Sokolowska J; Raj K; Polverelli N; Czerw T; Hernández-Boluda JC; McLornan D; Yakoub-Agha I Am J Hematol; 2023 Apr; 98(4):628-638. PubMed ID: 36606718 [TBL] [Abstract][Full Text] [Related]
15. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Wieduwilt MJ; Stock W; Advani A; Luger S; Larson RA; Tallman M; Appelbaum F; Zhang MJ; Bo-Subait K; Wang HL; Bhatt VR; Dholaria B; Eapen M; Hamadani M; Jamy O; Prestidge T; Pulsipher M; Ritchie D; Rizzieri D; Sharma A; Barba P; Sandmaier BM; de Lima M; Kebriaei P; Litzow M; Saber W; Weisdorf D Leukemia; 2021 Jul; 35(7):2076-2085. PubMed ID: 33785862 [TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study. Lu Y; Zhang JP; Zhao YL; Xiong M; Sun RJ; Cao XY; Wei ZJ; Zhou JR; Liu DY; Yang JF; Zhang X; Lu DP; Lu P Front Immunol; 2022; 13():1066748. PubMed ID: 36685540 [TBL] [Abstract][Full Text] [Related]
17. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Roos-Weil D; Dietrich S; Boumendil A; Polge E; Bron D; Carreras E; Iriondo Atienza A; Arcese W; Beelen DW; Cornelissen JJ; Kröger N; Milone G; Rossi G; Jardin F; Peters C; Rocha V; Sureda A; Mohty M; Dreger P; Blood; 2013 Jan; 121(3):440-6. PubMed ID: 23203822 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation. Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192 [TBL] [Abstract][Full Text] [Related]
19. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272 [TBL] [Abstract][Full Text] [Related]
20. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. McClune BL; Weisdorf DJ; Pedersen TL; Tunes da Silva G; Tallman MS; Sierra J; Dipersio J; Keating A; Gale RP; George B; Gupta V; Hahn T; Isola L; Jagasia M; Lazarus H; Marks D; Maziarz R; Waller EK; Bredeson C; Giralt S J Clin Oncol; 2010 Apr; 28(11):1878-87. PubMed ID: 20212255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]